Home › Research › Biomarkers
Glial fibrillary acidic protein immunohistochemical study of Alzheimer I & II astrogliosis in Wilson's disease
Ma KC, Ye ZR, Fang J, Wu JV.. Acta neurologica Scandinavica, 1988-10-01
Topic: Brain proteins, microglia and lab models
Plain-language summary
This study compared the relationships of the development of both Alzheimer I & II cells to reactive astrogliosis and also their distributional patterns in the demyelinated and non-demyelinated lesions in 6 cases of Wilson's disease by the use of PAP immunohistochemical technique for glial fibrillary acidic protein (GFAP). The development of GFAP positive Alzheimer I (A-I) cells was found to be directly proportional to the capability of reactive astrogliosis, and inversely proportional to the severity of Alzheimer II (A-II) change. The GFAP negative A-II cells could be identified morphologically into 2 subtypes: one with well-developed nuclei, the other with "shrunken" nuclei. They were believed to stand for the "compensatory" and "decompensatory" stages of this dynamic astrogliotic process respectively. The distribution patterns of these 2 types of astrogliosis were different: A-I cells were found only in the regions of demyelination with intensive reactive astrogliosis, while A-II cells were found diffusely in both the grey and white matter, affecting both the protoplasmic and fibrous astrocytes without special predilection.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Ma, K. C., Ye, Z. R., Fang, J., & Wu, J. V. (1988). Glial fibrillary acidic protein immunohistochemical study of Alzheimer I & II astrogliosis in Wilson's disease. Acta neurologica Scandinavica. https://doi.org/10.1111/j.1600-0404.1988.tb03659.x
Vancouver
Ma KC, Ye ZR, Fang J, Wu JV. Glial fibrillary acidic protein immunohistochemical study of Alzheimer I & II astrogliosis in Wilson's disease. Acta neurologica Scandinavica. 1988. doi:10.1111/j.1600-0404.1988.tb03659.x. PMID: 3066102.
BibTeX
@article{ma1988-3066102,
author = {Ma, K. C. and Ye, Z. R. and Fang, J. and Wu, J. V.},
title = {{Glial fibrillary acidic protein immunohistochemical study of Alzheimer I \& II astrogliosis in Wilson's disease}},
journal = {Acta neurologica Scandinavica},
year = {1988},
doi = {10.1111/j.1600-0404.1988.tb03659.x},
pmid = {3066102},
url = {https://doi.org/10.1111/j.1600-0404.1988.tb03659.x}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- This study compared the relationships of the development of both Alzheimer I & II cells to reactive astrogliosis and also their distributional patterns in the demyelinated and non-demyelinated lesions in 6 cases of Wilson's disease by the use of PAP immunohistochemical technique for glial fibrillary acidic protein (GFAP).
- The development of GFAP positive Alzheimer I (A-I) cells was found to be directly proportional to the capability of reactive astrogliosis, and inversely proportional to the severity of Alzheimer II (A-II) change.
- The GFAP negative A-II cells could be identified morphologically into 2 subtypes: one with well-developed nuclei, the other with "shrunken" nuclei.
- They were believed to stand for the "compensatory" and "decompensatory" stages of this dynamic astrogliotic process respectively.
- The distribution patterns of these 2 types of astrogliosis were different: A-I cells were found only in the regions of demyelination with intensive reactive astrogliosis, while A-II cells were found diffusely in both the grey and white matter, affecting both the protoplasmic and fibrous astrocytes without special predilection.
Why it matters
This small study of 6 Wilson's disease cases examined two types of astrocyte changes (Alzheimer I and II cells) and their relationship to reactive astrogliosis. It describes cell patterns in Wilson's disease tissue and does not test any treatment, prevention, or cure for Alzheimer's disease.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Evidence strengthLow
How this study scored 30/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it. We have no data on senior author's track record and institution's track record, so those were left out: it earned 28 of the 93 points we could judge it on, which is 30 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Acta neurologica Scandinavica) |
| Journal's citation record | 2 / 4 | Acta Neurologica Scandinavica: journal h-index 160 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 1988 — older than 20 years, still counted |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 3 / 7 | Cited 19 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.5 citations a year over 40 year(s) since 1988 |
| Impact for its field and year | 1 / 6 | Cited 0.6× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 1 / 6 | Cited by 1 other studies in this library |
| Still being cited | 0 / 4 | Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | 0 / 3 | OpenAlex lists 0 institution(s) in 0 countries — scores zero (affiliation lists can be incomplete) |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 3066102) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 28 / 93 | Scored on 18 of 20 parts. We have no data for the rest, so they are left out: 28 of the 93 points we could judge it on is 30 out of 100. |
| Total | 30 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription Unpaywall, Europe PMC and OpenAlex found no free copy of the full text (checked 10 Oct 2026), so the publisher may charge for it. The PubMed abstract is free.
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Later studies that cite this one
1 study in the alzhub library lists this one in its references.
Related studies in Biomarkers from nearby years
Also tagged “precursor”
1,337 studies in the library carry the topic tag “precursor”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,337 tagged studies.